Abstract: The disclosure relates to 1H-pyrazolo[3,4-d]pyrimidin-4-amine compounds and 1-nitro-5-amido-disubstituted furan compounds, or a pharmaceutically acceptable salt thereof, and methods for their use in treating, among other conditions, inflammatory diseases or an autoimmune diseases.

Abstract: Bis-aryl sulfonamide compounds and methods of using those compounds, e.g., in a method of enhancing or prolonging an immune response, are provided. For example, the compounds may be employed with a vaccine and optionally at least one other adjuvant and/or one or more TLR ligands, at least one MAP kinase inhibitor, or any combination thereof.

Abstract: A method to enhance an immune response in a mammal, and a composition comprising liposomes, a TLR4 agonist and a TLR7 agonist, are provided.

Abstract: Compounds useful as an adjuvant, e.g., formulas (I)-(VI) and uses thereof, for example, with immunogenic moieties or other adjuvants, are provided.

Abstract: A composition comprising silica shells conjugated to a TLR7 agonist and methods of using the composition are provided.

Abstract: Methods to isolate and expand tumor specific CD8+ T cells, and the use thereof, are provided. Also provided are method of using TLR7 agonists.

Abstract: The present invention provides a compound of Formula I for use in the treatment, amelioration and/or prevention of diseases and conditions associated with CETP activity, such as atherosclerosis and dyslipidemia, in a subject with high triglyceride level; wherein R1, X1, R7, R5, C, L and p are defined herein. The present invention further provides a combination of pharmacologically active agents for use in the treatment, amelioration and/or prevention of diseases and conditions associated with CETP activity, such as atherosclerosis and dyslipidemia, in a subject with high triglyceride levels.

Abstract: Methods of using TLR7 conjugates or TLR4 ligands, or a combination thereof, to treat fibrosis are provided.

Abstract: The present invention provides a compound of Formula I: for use in the treatment, amelioration and/or prevention of diseases and conditions associated with CETP activity, such as atherosclerosis and dyslipidemia, in a subject with high triglyceride level; wherein R1, X1, R7, R5, C, L and p are defined herein. The present invention further provides a combination of pharmacologically active agents for use in the treatment, amelioration and/or prevention of diseases and conditions associated with CETP activity, such as atherosclerosis and dyslipidemia, in a subject with high triglyceride levels.

Abstract: Block components having a conductive property are mounted on lands for connection to a harness so as to increase the height of the lands on a circuit board which is to be connected to windings.

Abstract: Provided herein, inter alia, are methods and compositions for modulating TLR-4.

Abstract: The invention provides uses for phospholipid conjugates of TLR agonists as enhancers of an innate immune response. Specifically, purine derivatives which are conjugated to a phospholipid or an analog thereof are disclosed as having activity as TLR7 agonists, capable of inducing an innate immune response upon administration in an effective amount to a subject. The phospholipid moiety of the TLR7 agonist contains one or more alkyl ether or ester moieties.

Abstract: This disclosure relates to compositions and methods useful to augment an immune response and methods and compositions for inducing immunogenicity to influenza antigens.

Abstract: Provided herein, inter alia, are methods and compositions for modulating TLR-4.

Abstract: Provided herein are compounds and methods for modulating an immune response in a subject in need thereof. Further provided herein are compounds and methods for modulating a toll-like receptor protein.

Abstract: Block components having a conductive property are mounted on lands for connection to a harness so as to increase the height of the lands on a circuit board which is to be connected to windings.

Abstract: Provided herein are small molecule conjugates that are agonists or antagonists of one or more toll-like receptors.

Abstract: The present invention provides a compound of Formula I: for use in the treatment, amelioration and/or prevention of diseases and conditions associated with CETP activity, such as atherosclerosis and dyslipidemia, in a subject with high triglyceride level; wherein R1, X1, R7, R5, C, L and p are defined herein. The present invention further provides a combination of pharmacologically active agents for use in the treatment, amelioration and/or prevention of diseases and conditions associated with CETP activity, such as atherosclerosis and dyslipidemia, in a subject with high triglyceride levels.

Abstract: The invention provides uses for phospholipid conjugates of TLR agonists, for instance in vaccines, and to prevent, inhibit or treat a variety of disorders including inflammation, cancer and pathogen, e.g., microbe, infection.

Abstract: Provided herein are small molecule conjugates that are agonists or antagonists of one or more toll-like receptors.